Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (31-40 of 221) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Structure and clinical relevance of the epidermal growth factor receptor in human cancerAmit Kumar, Edward T Petri, Balazs Halmos, et al.
Plos One|September 20, 2014
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1Guangyuan Li, Xiaoqi Wang, Hanina Hibshoosh, et al.
Thoracic Surgery Clinics|November 19, 2025
Advances in Systemic Therapy for Lung Cancer: Update on Biomarkers and Novel Drugs for Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)Mumtu Lalla, Ethan Pan, Vera Jokic, et al.
Lung Cancer (Auckland, N.Z.)|September 21, 2018
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literatureLei Deng, Janaki Sharma, Elizabeth Ravera, et al.
Expert Review of Respiratory Medicine|December 10, 2019
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancerMariam Alexander, Brian Ko, Remy Lambert, et al.
Clinical Lung Cancer|July 23, 2020
Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature ReviewYuanyuan Zhao, Linzhu Zhai, Lei Deng, et al.
Targeted Oncology|March 21, 2022
Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung CancerFawzi Abu Rous, Radhika Gutta, Pin Li, et al.
JCO Precision Oncology|February 17, 2022
Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the ClinicianAditi P Singh, Haiying Cheng, Xiaoling Guo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2018
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase InhibitionLei Deng, Lesli A Kiedrowski, Elizabeth Ravera, et al.
Translational Cancer Research|February 4, 2022
Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancerFeng Wang, Xuewen Liu, Boris A Bartholdy, et al.
Pageof 23

Showing results (31-40 of 221) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2008
Structure and clinical relevance of the epidermal growth factor receptor in human cancerAmit Kumar, Edward T Petri, Balazs Halmos, et al.
Plos One|September 20, 2014
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1Guangyuan Li, Xiaoqi Wang, Hanina Hibshoosh, et al.
Thoracic Surgery Clinics|November 19, 2025
Advances in Systemic Therapy for Lung Cancer: Update on Biomarkers and Novel Drugs for Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)Mumtu Lalla, Ethan Pan, Vera Jokic, et al.
Lung Cancer (Auckland, N.Z.)|September 21, 2018
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literatureLei Deng, Janaki Sharma, Elizabeth Ravera, et al.
Expert Review of Respiratory Medicine|December 10, 2019
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancerMariam Alexander, Brian Ko, Remy Lambert, et al.
Clinical Lung Cancer|July 23, 2020
Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature ReviewYuanyuan Zhao, Linzhu Zhai, Lei Deng, et al.
Targeted Oncology|March 21, 2022
Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung CancerFawzi Abu Rous, Radhika Gutta, Pin Li, et al.
JCO Precision Oncology|February 17, 2022
Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the ClinicianAditi P Singh, Haiying Cheng, Xiaoling Guo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2018
Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase InhibitionLei Deng, Lesli A Kiedrowski, Elizabeth Ravera, et al.
Translational Cancer Research|February 4, 2022
Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancerFeng Wang, Xuewen Liu, Boris A Bartholdy, et al.
Pageof 23